Insight

Biagio Ricciuti: 5-year update from the NADIM trial

Biagio Ricciuti/X

Oct 16, 2024, 17:00

Biagio Ricciuti: 5-year update from the NADIM trial

Biagio Ricciuti shared a post on X about a recent paper by Mariano Provencio et al. published in The Lancet Oncology.

“5-year update from the NADIM trial (perioperative CT and nivo in stage III NSCLC)

5-year PFS 65% OS 69.3%
pCR: PFS 92% and OS 95.8%
Non-pCR: PFS 60% and OS 66%
2 patients with pCR had disease progression and had mutations in KEAP1 and EGFR.”

“Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial”

Authors: Mariano Provencio, Ernest Nadal, Amelia Insa, Atocha Romero, Alberto Cruz-Bermúdez et al.

Biagio Ricciuti: 5-year update from the NADIM trial

More posts featuring Biagio Ricciuti.

Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.

Alberto Cruz-Bermúdez. Amelia Insa Atocha Romero Biagio Ricciuti cancer Dana-Farber Cancer Institute Ernest Nadal Mariano Provencio NADIM trial nivolumab NSCLC OncoDaily Oncology The Lancet Oncology

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage